Abstract
Inflammation in Parkinson’s disease (PD) is a continuous process and might be implicated in the progression of neuronal degeneration. Taking this into account, we proposed a new protocol with multiple and consecutive intranigral lipopolysaccharide (LPS) administration in order to analyze its effects on cognitive behavior. Additionally, striatal concentrations of the neurotransmitters dopamine (DA) and serotonin and their respective metabolites were assessed in three different time-points with the purpose of identifying the consecutive and cumulative effects of LPS infusions. We demonstrated that with a minimum administered dose there was stabilization of neuronal damage as revealed by absence of synergic effect on DA concentration. Although the DA decrease (–43%) generates an animal model of early phase of PD, without apparent motor impairment, the LPS group exhibited deficit in episodic-like memory behavior from the first time-point until the last one, indicating persisted disturbances in memory-recognition responses. These findings provide evidence that multiple intranigral LPS infusions are not sufficient to cause cumulative and progressive damage to dopaminergic neurons, but confirm that the LPS model can be adopted as a useful tool providing insight about the cognitive impairment observed in pre-motor phase of PD.
Keywords: Parkinson’s disease, lipopolysaccharide, cognitive impairment, novel-object recognition test.
CNS & Neurological Disorders - Drug Targets
Title:Multiple Intranigral Unilateral LPS Infusion Protocol Generates a Persistent Cognitive Impairment without Cumulative Dopaminergic Impairment
Volume: 12 Issue: 7
Author(s): Ana Marcia Delattre, Bruno Carabelli, Marco Aurélio Mori, Claudia Pudell, Danielle R.B.L. da Silva, Isabela Menezes, Paula R.G. Kempe, Pedro Vinícius Staziaki, Patrícia A. Dombrowski, Claudio da Cunha, Marcelo M.S. Lima and Anete C. Ferraz
Affiliation:
Keywords: Parkinson’s disease, lipopolysaccharide, cognitive impairment, novel-object recognition test.
Abstract: Inflammation in Parkinson’s disease (PD) is a continuous process and might be implicated in the progression of neuronal degeneration. Taking this into account, we proposed a new protocol with multiple and consecutive intranigral lipopolysaccharide (LPS) administration in order to analyze its effects on cognitive behavior. Additionally, striatal concentrations of the neurotransmitters dopamine (DA) and serotonin and their respective metabolites were assessed in three different time-points with the purpose of identifying the consecutive and cumulative effects of LPS infusions. We demonstrated that with a minimum administered dose there was stabilization of neuronal damage as revealed by absence of synergic effect on DA concentration. Although the DA decrease (–43%) generates an animal model of early phase of PD, without apparent motor impairment, the LPS group exhibited deficit in episodic-like memory behavior from the first time-point until the last one, indicating persisted disturbances in memory-recognition responses. These findings provide evidence that multiple intranigral LPS infusions are not sufficient to cause cumulative and progressive damage to dopaminergic neurons, but confirm that the LPS model can be adopted as a useful tool providing insight about the cognitive impairment observed in pre-motor phase of PD.
Export Options
About this article
Cite this article as:
Delattre Marcia Ana, Carabelli Bruno, Mori Aurélio Marco, Pudell Claudia, Silva R.B.L. da Danielle, Menezes Isabela, Kempe R.G. Paula, Staziaki Vinícius Pedro, Dombrowski A. Patrícia, Cunha da Claudio, Lima M.S. Marcelo and Ferraz C. Anete, Multiple Intranigral Unilateral LPS Infusion Protocol Generates a Persistent Cognitive Impairment without Cumulative Dopaminergic Impairment, CNS & Neurological Disorders - Drug Targets 2013; 12 (7) . https://dx.doi.org/10.2174/18715273113129990074
DOI https://dx.doi.org/10.2174/18715273113129990074 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Sphingolipid Signaling and Hematopoietic Malignancies: To the Rheostat and Beyond
Anti-Cancer Agents in Medicinal Chemistry Mild Cognitive Impairment: At the Crossroad of Neurodegeneration and Vascular Dysfunction
Current Alzheimer Research Increased CRMP2 Phosphorylation is Observed in Alzheimers Disease; Does this Tell us Anything About Disease Development?
Current Alzheimer Research Mitochondrial Mechanisms of Metabolic Reprogramming in Proliferating Cells
Current Medicinal Chemistry Editorial [Hot Topic: In Silico (Guest Editor: Alexandre G. de Brevern)]
Infectious Disorders - Drug Targets Anti PD-1 and PDL-1 Immunotherapy in the Treatment of Advanced Non- Small Cell Lung Cancer (NSCLC): A Review on Toxicity Profile and its Management
Current Drug Safety Antidepressant Brain Stimulation Techniques
Current Psychiatry Reviews Review of Pediatric Osteoarticular Infections
Reviews on Recent Clinical Trials Intracerebrally Applied Botulinum Neurotoxin in Experimental Neuroscience
Current Pharmaceutical Biotechnology Progress in Intra-Articular Drug Delivery Systems for Osteoarthritis
Current Drug Targets Cell Death and Survival Through the Endoplasmic Reticulum- Mitochondrial Axis
Current Molecular Medicine Non-Antidepressant Psychopharmacologic Treatment of Specific Phobias
Current Clinical Pharmacology Is Nicotine Protective Against Parkinson´s Disease? An Experimental Analysis
CNS & Neurological Disorders - Drug Targets Kinetic Study on the Effects of Extremely Low Frequency Electromagnetic Field on Catalase, Cytochrome P450 and Inducible Nitric Oxide Synthase in Human HaCaT and THP-1 Cell Lines
CNS & Neurological Disorders - Drug Targets Metabotropic Glutamate Receptor 7 (mGluR7) as a Target for Modulating Pain-evoked Activities of Neurons in the Hippocampal CA3 Region of Rats
CNS & Neurological Disorders - Drug Targets Crimean-Congo Hemorrhagic Fever Virus in Pakistan
Infectious Disorders - Drug Targets How Close are We in Achieving Safe, Affordable and Reversible Male Contraceptives?
Endocrine, Metabolic & Immune Disorders - Drug Targets Recent Progress and Challenges in Nanotechnology for Biomedical Applications: An Insight into the Analysis of Neurotransmitters
Recent Patents on Nanotechnology Dystonia Associated with Lamotrigine Therapy: A Case Report and Review of the Literature
Current Drug Safety Factors of Rapid Cognitive Decline in Late Onset Alzheimer's Disease
Current Aging Science